Oncology

The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

This interview discusses major themes from OPC 2026, including advances in immunotherapy delivery, practical applications of ASCO and EHA data, and the expanding role of oncology pharmacists in optimizing patient care.

The new indication is for those aged 12 years and older with unresectable or metastatic SS who received prior chemotherapy and are positive for certain genetic subtypes.

This interview discusses common challenges in precision medicine implementation and how oncology pharmacists can build expertise in biomarker interpretation, pharmacogenomics, and multidisciplinary care.

Findings from a retrospective analysis show that montelukast prophylaxis significantly reduced rituximab infusion-related reactions, particularly among patients receiving treatment for oncology indications.

This OPC interview discusses emerging personalized immunotherapy approaches in melanoma, evolving toxicity management strategies, and the future role of cancer vaccines in cutaneous oncology.

Kim Nguyen, PharmD, discusses findings from her OPC abstract on cardiovascular toxicities and drug-drug interactions associated with BTK inhibitors, highlighting strategies for individualized treatment selection and patient monitoring.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.

The multiple myeloma (MM) approval was based on phase 3 IRAKLIA data demonstrating noninferior efficacy and reduced infusion-related reactions compared with intravenous administration.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This OPC interview discusses the growing importance of molecular testing, care coordination, and oral oncology therapies in optimizing outcomes for patients with gastrointestinal malignancies.

The growing importance of comprehensive biomarker testing, toxicity management, and the expanding role of targeted therapies in early-stage thoracic malignancies.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This OPC interview discusses emerging standards of care in genitourinary cancers, the growing role of molecular testing and minimal residual disease monitoring, and how oncology pharmacists can optimize treatment management.

This OPC interview discusses practice-changing updates from ASCO and EHA, including advances in bispecific antibodies, breast cancer treatment strategies, and multiple myeloma sequencing considerations.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Oncology pharmacists step into precision care—tracking mRNA vaccines, frailty-guided supportive therapy, NGS actionability, and new thoracic targets.

New GI cancer data highlight emerging targeted therapies, ctDNA-guided surveillance, and pharmacist-led workflows to boost outcomes.

This interview discusses candidate selection, toxicity monitoring, access considerations, and evolving clinical applications of menin inhibitors in acute myeloid leukemia (AML).

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

How oncology pharmacists evaluate emerging clinical data, overcome implementation barriers, and stay current with rapidly evolving advances in precision oncology.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

New breast cancer trial insights reshape metastatic care: sacituzumab benefits broadly, oral SERDs lag, denosumab every 12 weeks suffices.